Investigational Compound News
Learn more about Bristol-Myers Squibb’s research and development efforts and track the progress of investigational compounds in the news. Our pipeline is one of the most innovative in the industry.
We will post periodic updates about select Phase 1 and 2 investigational compounds on this page, as new data are presented or published.
Pipeline Asset Update for Daclatasvir (DCV; BMS-790052)
Discovered by Bristol-Myers Squibb through a genomics approach, daclatasvir, also known as BMS-790052 or DCV, is the first NS5A replication complex inhibitor to be investigated in hepatitis C clinical trials.
Conference on Retroviruses and Opportunistic Infections (CROI), 2012
BMS-663068 (attachment inhibitor)
Conference on Retroviruses and Opportunistic Infections (CROI), 2011
BMS-663068 is an HIV-1 attachment inhibitor in development for the treatment of HIV-1 infection
To receive notifications when updates to this page are available, media and investors can sign for our “Investigational Compound News” RSS feed.
Get RSS News Alerts